Join MSK's Dr. Michael Morris at #ASCO26 as he presents results from CONVERGE-01 Part 3 evaluating Ac-225 rosopatamab tetraxetan in patients w/ metastatic castration-resistant #prostatecancer previously treated with Lu-PSMA therapy.
Learn more: meetings.asco.org/meetings/202...
